Abstract
Prion diseases are fatal neurodegenerative conditions that affect humans and animals. Rapid and accurate sequencing of the prion gene PRNP is paramount to human prion disease diagnosis and for animal surveillance programmes. Current methods for PRNP genotyping involve sequencing of small fragments within the protein-coding region. The contribution of variants in the non-coding regions of PRNP including large structural changes is poorly understood. Here we use long-range PCR and Nanopore sequencing to sequence the full length of PRNP, including its regulatory region, in 25 samples from blood and brain of individuals with various prion diseases. Nanopore sequencing detected the same variants as identified by Sanger sequencing, including repeat expansions/contractions. Nanopore identifies additional single-nucleotide variants in the non-coding regions of PRNP, but no novel structural variants were discovered. Finally, we explore somatic mosaicism of PRNP’s octapeptide repeat region, which is a hypothetical cause of sporadic prion disease. While we find changes consistent with somatic mutations, we demonstrate that they may have been generated by the PCR. Our study illustrates the accuracy of Nanopore sequencing for rapid and field prion disease diagnosis and highlights the need for single-molecule sequencing methods for the detection of somatic mutations.
Competing Interest Statement
Prof. Collinge is a director and shareholder of D-Gen Limited (London), an academic spinout company working in the field of prion disease diagnosis, decontamination and therapeutics. Francois Kroll owns stocks in Oxford Nanopore Technologies and Pacific Biosciences. All other authors declare no competing interests.
Funding Statement
This study was funded by the UK Medical Research Council and the National Institute of Health Research (NIHR) Biomedical Research Centre at UCL Hospitals NHS Foundation Trust. S.M. and J.C. are NIHR Senior Investigators. F. K. is supported and funded by the Leonard Wolfson PhD Programme in Neurodegeneration. A.D. is supported by the Onassis Foundation - Scholarship ID: F ZQ 022-1/2020-2021.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All experimental protocols were approved by the London Queen Square Research Ethics Committee (reference 05/Q0505/113).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Code will be made available at https://github.com/athanadd/prnp-nanopore-seq and https://github.com/francoiskroll/prnp_nanopore. Data will be made available as a Zenodo repository.